Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IB003
- Development stage
- Preclinical
- Lead developer
- Interactome Biotherapeutics
- Modality
- Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
IB003 is an early-stage therapeutic candidate being developed by Interactome Biotherapeutics for neuroimmunological indications. It utilizes a dual-modality approach, combining gene therapy with small extracellular vesicles (sEVs or exosomes) as a delivery platform. The program leverages the company's proprietary Native Nano Platform, which uses exosomes as natural drug delivery vehicles to transport therapeutic genetic cargo to target cells. This approach aims to modulate inflammation and promote cellular regeneration within the nervous system.
Beyond the preview
Go deeper on IB003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IB003.